Author:
Spalgais Sonam,Safwan M. Ahmed,Mrigpuri Parul,Kumar Raj
Abstract
The Adverse Drug Reactions (ADRSs) to Anti-Tubercular Therapy (ATT) have been reported from 8% to 85% worldwide, while the prevalence of ADRSs to 1st line ATT from India reported 2.3% to 17%, with more during the intensive phase and daily regime. However, cutaneous ADRSs related to ATT are less commonly seen. Common cutaneous ADRSs are maculopapular rash, urticarial, erythema multiforme, exfoliative dermatitis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Among the 1st line ATT, pyrazinamide is the most common cause at 2.38%, and isoniazid is reported the least at 0.98%. Exfoliated dermatitis is rarely seen with 1st line ATT therapy limited to some case reports and case series.
Reference13 articles.
1. Singh A, Prasad R, Balasubramanian V, et al. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clin Epidemiol Glob Health 2015;3:S80-90.
2. Sharma RK, Verma GK, Tegta GR, et al. Spectrum of cutaneous adverse drug reactions to antitubercular drugs and safe therapy after rechallenge - A retrospective study. Indian Dermatol Online J 2020;11:177-81.
3. Varghese AM, Kandra N, Uppala PK, et al. Anti-Tubercular Therapy (ATT) induced exfoliative dermatitis A case series. Indian J Tuberc 2023;70:253-7.
4. Dua R, Sindhwani G, Rawat J. Exfoliative dermatitis to all four first line oral anti-tubercular drugs. Indian J Tuberc 2010;57:53-6.
5. World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-susceptible tuberculosis treatment. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK581329/
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Antituberculars;Reactions Weekly;2024-07-27